Core Oncology Signs Contract with HealthTrust Purchasing Group
SANTA BARBARA, California, January 28, 2010 - Core Oncology, Inc. today announced a three-year agreement with HealthTrust Purchasing Group, LP and its members. Core Oncology will supply ProstaSeed iodine-125, TheraSeed palladium-103 brachytherapy seeds for the treatment of prostate cancer, and VISICOIL™ linear fiducial markers used for IGRT & IMRT therapies. The term of this agreement is February 1, 2010 through January 31, 2013.
“We are very pleased to be contracted with HealthTrust for the fourth time in a decade,” said Travis Gay, President and CEO of Core Oncology. “We are proud to be associated with one of the largest GPOs in the industry.”
About Core Oncology
Core Oncology was founded on September 15, 2006 by the existing management of the brachytherapy business owned by Coloplast, formerly Mentor, for the sole purpose of enhancing the levels of service and continuing our pursuit of innovation within the field of radiation oncology. Our philosophy is to make our customers and their trusted patients the focus of our business. Initially formed in 1997, Mentor’s brachytherapy division entered the radiation oncology market as the first company to offer both iodine and palladium brachytherapy sources. Since then the division has developed and successfully launched numerous innovative delivery technologies and services, including the Isoloader® workstation, prescription loaded needle services and the C20™proprietary cartridge systems for the Mick® applicator. The management team that has facilitated the growth and development of the brachytherapy division is the same team that now manages Core Oncology.
To learn more about the tools and services Core Oncology provides, visit www.coreoncology.com.
About HealthTrust Purchasing Group
HealthTrust Purchasing Group, headquartered in Brentwood, Tenn., is a group purchasing organization that supports over 1,400 not-for-profit and for-profit acute care facilities, as well as ambulatory surgery centers, physician practices, and alternate care sites. With an annual purchasing volume by its members of more than $17 billion, HealthTrust is committed to obtaining the best price for clinically-recommended products, ensuring their timely delivery and continuously evaluating and improving its services to the patients, physicians and clinicians it serves. To learn more about the tools and services HealthTrust provides, visit http://www.healthtrustpg.com.
